Last Updated: October 1, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Mexico: These 38 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Generic Entry Dates in Other Countries

African Regional IP Organization (ARIPO) Argentina Australia Austria Brazil Canada Chile China Colombia Costa Rica Croatia Cuba Cyprus Denmark Dominican Republic Ecuador Eurasian Patent Organization European Patent Office Finland France Georgia, Republic of Germany Guatemala Honduras Hong Kong Hungary Israel Italy Japan Jordan Lithuania Luxembourg Malaysia Montenegro Morocco Netherlands New Zealand Nicaragua Norway Panama Peru Philippines Poland Portugal Russian Federation San Marino Saudi Arabia Serbia Singapore Slovenia South Africa South Korea Spain Taiwan Tunisia Turkey Ukraine United Kingdom United States Uruguay
Preferred citation:
Friedman, Yali, "Mexico: These 38 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can TYMLOS (abaloparatide) generic drug versions launch in Mexico?

Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Mexico Patent 2,009,003,569
Patent Title: METODO DE ADMINISTRACION DE FARMACOS PARA LA PROTEINA ANABOLICA OSEA. (METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN.)

Drug Price Trends for TYMLOS
TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. Additional details are available on the abaloparatide profile page.

When can INREBIC (fedratinib hydrochloride) generic drug versions launch in Mexico?

Generic name: fedratinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 26, 2026
Generic Entry Controlled by: Mexico Patent 391,408

INREBIC is a drug marketed by Bristol-myers. There are five patents protecting this drug. There has been litigation on patents covering INREBIC

See drug price trends for INREBIC.

The generic ingredient in INREBIC is fedratinib hydrochloride. Additional details are available on the fedratinib hydrochloride profile page.

When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch in Mexico?

Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 08, 2026
Generic Entry Controlled by: Mexico Patent 2,007,008,075
Patent Title: COMBINACIONES FARMACEUTICAS DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA Y UN INHIBIDOR DE ENDOPEPTIDASA NEUTRAL (NEP). (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR.)

Drug Price Trends for ENTRESTO SPRINKLE
ENTRESTO SPRINKLE is a drug marketed by Novartis. There are three patents protecting this drug. There has been litigation on patents covering ENTRESTO SPRINKLE

See drug price trends for ENTRESTO SPRINKLE.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. Additional details are available on the sacubitril; valsartan profile page.

When can KORSUVA (difelikefalin acetate) generic drug versions launch in Mexico?

Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Mexico Patent 2,009,004,999
Patent Title: AMIDAS DE PEPTIDOS SINTETICOS Y DIMEROS DE LAS MISMAS. (SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF.)

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.

When can KORSUVA (difelikefalin acetate) generic drug versions launch in Mexico?

Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2026
Generic Entry Controlled by: Mexico Patent 2,009,005,000
Patent Title: AMIDAS DE PEPTIDOS SINTETICOS. (SYNTHETIC PEPTIDE AMIDES.)

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.

When can ZTALMY (ganaxolone) generic drug versions launch in Mexico?

Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Mexico Patent 2,008,006,888
Patent Title: FORMULAS Y METODOS PARA LA MANUFACTURA Y USO DE LA GANAXOLONA. (GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF.)

ZTALMY is a drug marketed by Immedica Pharma. There are eleven patents protecting this drug. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. Additional details are available on the ganaxolone profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Mexico?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Mexico Patent 2,009,005,909
Patent Title: SAL FUMARATO DE (ALFA S, BETA R)-6-BROMO-ALFA-[2-(DIMETILAMINO)ETI L]-2-METOXI-ALFA-1-NAFTALENIL-BETA-FENIL-3-QUINOLINAETANOL. (FUMARATE SALT OF (ALPHA S, BETA R)-6-BROMO-ALPHA-[2-(DIMETHYLAMIN O)ETHYL]-2-METHOXY-ALPHA-1-NAPHTHALENYL-BETA-PHENYL-3-QUINOLINEE THANOL.)

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Mexico?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Mexico Patent 2,009,006,081

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Mexico?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Mexico Patent 2,010,002,336

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in Mexico?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Mexico Patent 2,008,007,685
Patent Title: COMPOSICIONES TERAPEUTICAS. (THERAPEUTIC COMPOSITIONS COMPRISING INGENOL-3-ANGELATE.)

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Mexico?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Mexico Patent 2,008,008,152
Patent Title: COMPUESTOS HETEROCICLICOS BICICLICOS. (BICYCLIC HETEROARYL COMPOUNDS.)

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Mexico?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 22, 2026
Generic Entry Controlled by: Mexico Patent 343,042
Patent Title: COMPUESTOS HETEROARILICOS BICICLICOS. (BICYCLIC HETEROARYL COMPOUNDS.)

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in Mexico?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Mexico Patent 352,876
Patent Title: METODO PARA PREPARAR PARTICULAS QUE COMPRENDEN RECUBRIMIENTO DE OXIDO DE METAL Y PARTICULAS CON RECUBRIMIENTO DE OXIDO DE METAL. (METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING.)

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Mexico?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Mexico Patent 2,009,008,828
Patent Title: COMPOSICIONES DE ENZIMAS DIGESTIVAS ESTABLES. (STABLE DIGESTIVE ENZYME COMPOSITIONS.)

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Mexico?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Mexico Patent 2,009,008,828
Patent Title: COMPOSICIONES DE ENZIMAS DIGESTIVAS ESTABLES. (STABLE DIGESTIVE ENZYME COMPOSITIONS.)

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in Mexico?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: Mexico Patent 2,009,010,210
Patent Title: FORMULACIONES DE COMPRIMIDOS QUE CONTIENEN SALES DE 8-[{1-(3,5-BIS-(TRIFLUOROMETIL)FENIL)-ETOXI}-METIL]-8-FENIL-1,7-D IAZA-SPIRO[4.5]DECAN-2-ONA Y COMPRIMIDOS ELABORADOS A PARTIR DE ESTAS. (TABLET FORMULATIONS CONTAINING 8-[{1-(3,5-BIS-(TRIFLUOROMETHYL)PH ENYL)-ETHOXY}-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM.)

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can AMYVID (florbetapir f-18) generic drug versions launch in Mexico?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 26, 2027
Generic Entry Controlled by: Mexico Patent 2,008,012,527

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. Additional details are available on the florbetapir f-18 profile page.

When can INLYTA (axitinib) generic drug versions launch in Mexico?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Mexico Patent 2,009,010,761

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Mexico?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Mexico Patent 2,008,012,945
Patent Title: MODULADORES DE TRANSPORTADORES DE CARTUCHO DE UNION A ADENOSINA-TRIFOSFATO CELULAR (ATP). (MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS.)

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in Mexico?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: Mexico Patent 2,009,010,600

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Mexico?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Mexico Patent 2,009,011,881

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Mexico?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Mexico Patent 2,008,014,289
Patent Title: COMPUESTOS HETEROARILICOS ACETILENICOS. (ACETYLENIC HETEROARYL COMPOUNDS.)

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Mexico?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Mexico Patent 2,008,014,290
Patent Title: COMPUESTOS HETEROARILICOS MONOCICLICOS. (MONOCYCLIC HETEROARYL COMPOUNDS.)

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Mexico?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Mexico Patent 2,009,012,182

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Mexico?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Mexico Patent 2,009,012,536
Patent Title: UNA COMPOSICION DE LIBERACION PROLONGADA QUE COMPRENDE UN DERIVADO DE SOMATOSTATINA EN MICROPARTICULAS. (AN EXTENDED-RELEASE COMPOSITION COMPRISING A SOMATOSTATIN DERIVATIVE IN MICROPARTICLES.)

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Mexico?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Mexico Patent 2,009,013,402

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Mexico?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Mexico Patent 342,814

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Mexico?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Mexico Patent 2,009,013,664
Patent Title: COMPOSICION, METODO Y PREPARACION DEL ACIDO BILIAR SINTETICO. (SYNTHETIC BILE ACID COMPOSITION, METHOD, AND PREPARATION.)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Mexico?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Mexico Patent 360,094
Patent Title: COMPOSICIÓN, MÉTODO Y PREPARACIÓN DEL ÁCIDO BILIAR SINTÉTICO. (SYNTHETIC BILE ACID COMPOSITION, METHOD, AND PREPARATION.)

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can CARDAMYST (etripamil) generic drug versions launch in Mexico?

Generic name: etripamil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 20, 2027
Generic Entry Controlled by: Mexico Patent 2,009,014,052
Patent Title: BLOQUEADORES DEL CANAL DE CALCIO DE FENILALQUILAMINA DE ACCION CORTA Y SUS USOS. (SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF.)

Drug Price Trends for CARDAMYST
CARDAMYST is a drug marketed by Milestone Pharms Usa. There are six patents protecting this drug. There has been litigation on patents covering CARDAMYST

See drug price trends for CARDAMYST.

The generic ingredient in CARDAMYST is etripamil. Additional details are available on the etripamil profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch in Mexico?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Mexico Patent 2,008,015,377

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch in Mexico?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Mexico Patent 367,155

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in Mexico?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Mexico Patent 2,008,015,377

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fourteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in Mexico?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Mexico Patent 367,155

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fourteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Mexico?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Mexico Patent 2,008,015,377

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Mexico?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2027
Generic Entry Controlled by: Mexico Patent 367,155

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Mexico?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Mexico Patent 2,009,000,404
Patent Title: SALES DE BENZODIAZEPINA DE ACCION CORTA Y SUS FORMAS POLIMORFICAS. (SHORT-ACTING BENZODIAZEPINE SALTS AND THEIR POLYMORPHIC FORMS.)

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Mexico?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Mexico Patent 2,010,001,256

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Mexico?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Mexico Patent 2,019,003,639

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Mexico?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Mexico Patent 363,238

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Mexico?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Mexico Patent 363,701

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Mexico?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Mexico Patent 371,802

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in Mexico?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Mexico Patent 2,010,001,627
Patent Title: COMPOSICIONES DE DHEA PARA EL TRATAMIENTO DE LA MENOPAUSIA. (DHEA COMPOSITIONS FOR TREATING MENOPAUSE.)

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Mexico?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Mexico Patent 2,009,001,853

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Mexico?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Mexico Patent 340,403

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can VIZAMYL (flutemetamol f-18) generic drug versions launch in Mexico?

Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 30, 2027
Generic Entry Controlled by: Mexico Patent 2,010,002,196
Patent Title: COMPOSICION RADIOFARMACEUTICA. (RADIOPHARMACEUTICAL COMPOSITION.)

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. Additional details are available on the flutemetamol f-18 profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in Mexico?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: Mexico Patent 2,010,003,588
Patent Title: PROCESO PARA LA MANUFACTURA DE UN PRODUCTO FARMACEUTICO. (PROCESS FOR THE MANUFACTURE OF A PHARMACEUTICAL PRODUCT.)

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Mexico?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Mexico Patent 2,010,005,346
Patent Title: COMPOSICIONES FARMACEUTICAS. (PHARMACEUTICAL COMPOSITIONS.)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Mexico?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Mexico Patent 2,010,005,632
Patent Title: ANALOGOS DE AMINOGLUCOSIDOS ANTIBACTERIANOS. (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS.)

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Mexico?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Mexico Patent 2,010,005,776

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Mexico?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Mexico Patent 2,011,002,449

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Mexico?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Mexico Patent 2,011,002,450

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Mexico?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Mexico Patent 2,010,005,776

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Mexico?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Mexico Patent 2,011,002,449

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Mexico?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Mexico Patent 2,011,002,450

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

Mexico Branded vs Generic Drug Markets Assessment, Regulation, and IP Opportunities: Growth, Barriers, Exclusivity, and Entry Risk

Last updated: May 12, 2026

Mexico’s pharmaceutical market combines large branded volume with an accelerating generic footprint shaped by COFEPRIS reimbursement policy, price controls, substitution rules, and a fast-moving IP and regulatory compliance environment. The headline for investors and licensors: generics can scale quickly, but brand incumbents and originators retain leverage through formulation, method-of-use, and process patents plus complex dossier and labeling requirements that raise “time-to-market” risk for challengers. The regulatory agenda that matters most for competitive strategy is COFEPRIS dossier predictability, biologics/biosimilars oversight, advertising and promotion constraints, and the practical enforcement of substitution and interchangeability.

What is the size and growth profile of Mexico’s branded vs generic drug markets?

Mexico’s retail and payer exposure is concentrated in chronic-care therapeutic classes, where treatment continuity supports branded revenue durability. Generics capture share most effectively where (1) patent and exclusivity barriers have cleared, (2) payers and procurement systems prefer lower net prices, and (3) prescribing behavior and substitution rules support interchangeability.

Market structure drivers (high level)

  • Chronic therapy mix: Statins, antihypertensives, diabetes therapies, and anti-infectives drive volume.
  • Price pressure: Public procurement and reimbursement mechanisms pressure net pricing, pulling formularies toward generics.
  • Brand equity vs substitution: Branded products remain preferred where physicians anchor on clinical familiarity, but substitution and pharmacist-level interchange can shift share.

Commercial implication

  • For branded portfolios, strategy centers on (a) extending IP tail via secondary patents and lifecycle management and (b) defending formularies through payer contracting and bundle positioning.
  • For generics, strategy centers on speed-to-approval, manufacturing compliance, and dossier resilience to COFEPRIS information requests.

How does COFEPRIS regulation shape generic entry timelines and approval risk?

COFEPRIS controls market authorization via quality, safety, and efficacy dossier review and sets enforceable requirements for manufacturing and labeling. Generic timelines depend on dossier completeness, inspection readiness, and local compliance to Mexican technical standards.

Key regulatory friction points for generic applicants

  • Dossier content and module completeness: Missing or inconsistent Chemistry, Manufacturing, and Controls (CMC) details slow review.
  • Manufacturing compliance and inspections: Evidence of GMP compliance and traceability of APIs and finished product manufacture are gating items.
  • Bioequivalence and bridging strategy: For generics, bioequivalence evidence must meet Mexican expectations for quality equivalence and performance.
  • Labeling and packaging compliance: COFEPRIS approval is sensitive to packaging language, instructions, and safety statements aligned to Mexican requirements.

Operational implication

  • Applicants win by reducing iteration risk: align CTD modules, lock validated processes, and prepare for facility inspection readiness before filing.

What patents protect branded drugs in Mexico and how do they affect generic competition?

Mexico patent protection is a practical lever for originators because it can block approval for generics that rely on the protected “innovator” basis under the regulatory linkage framework. The patent estate’s composition matters: product claims, formulation claims, use claims, and manufacturing/process claims can all shape entry calendars.

Common patent categories relevant to Mexico entry

  • Compound and composition-of-matter: Base active ingredient and salt/polymorph protection.
  • Formulation and dosage form: Excipients, coatings, release profiles, particle size, and stability-improving compositions.
  • Method-of-use: Dosing regimens, therapeutic indications, and patient subgroups.
  • Manufacturing/process: Steps, impurities control, or process parameters.

Practical IP impact

  • Even when the core compound patent approaches expiry, secondary patents can extend effective exclusivity, especially for line extensions and stable-release formulations.

When does Mexico generic exclusivity end, and what does “regulatory exclusivity” mean in practice?

Generic entry is timed by both patent expiry and regulatory exclusivity constructs that can delay reliance on innovator data or limit certain approvals. In Mexico, the decisive barrier for many competitors is the intersection of (1) patent validity period and (2) COFEPRIS’s regulatory linkage approach to protected products.

Timing constructs that matter

  • Patent term: Ends when patent rights expire or lapse.
  • Regulatory linkage barriers: Generic applications that would rely on protected innovator basis can be stayed or blocked while patents are in force, depending on the product and legal status.
  • Regulatory market authorization vs. substitution: Approval timing does not automatically translate into market share if substitution rules or reimbursement coverage remain restrictive.

Commercial implication

  • The effective exclusivity window is often longer than “first expiry” because of litigation and continuing-life patents that keep COFEPRIS linkage tied to the innovator’s protected status.

What is the Orange Book equivalent in Mexico and how do patent listings work?

Mexico does not use the US “Orange Book” construct, but Mexico’s linkage and COFEPRIS information systems function as the operational equivalent for patent status and regulatory protection. For entry strategists, the core task is tracking the innovator’s patent status as recognized through COFEPRIS processes and the applicant’s regulatory reliance strategy.

Entry analysis checklist

  • Confirm the innovator’s IP status in the relevant linkage framework.
  • Map patent claims to product attributes (salt/formulation/dose/use) that the generic would replicate.
  • Build the regulatory plan around whether the generic can proceed without triggering protected reliance barriers.

What Paragraph IV equivalent challenges exist in Mexico, and how are they executed?

Mexico’s patent challenge practice differs from the US Paragraph IV framework. Competitors typically challenge patent validity or argue non-infringement through Mexican legal pathways while pursuing regulatory authorization on the basis allowed under Mexican rules.

Practical challenge mechanics

  • Injunction and stay risk: If a generic filing is linked to an innovator patent, the competitor faces potential regulatory delay or legal stays.
  • Validity and infringement arguments: Patent invalidity challenges and non-infringement positions affect whether a generic can progress.
  • Litigation duration: Timing uncertainty can be material, affecting go-to-market.

Commercial implication

  • Competitors should model legal duration as a time-to-market variable. For licensing and investment, the value driver is the enforceability strength of the innovator’s patent estate.

What biosimilar pathways exist in Mexico and how do they differ from generic drugs?

Mexico regulates biologics and biosimilars under COFEPRIS oversight with a framework that relies on comparability, clinical evidence, and quality-by-design evidence. Biosimilar entry risk is often higher than small-molecule generics due to evidence requirements, manufacturing complexity, and immunogenicity considerations.

Biosimilar risk drivers

  • Comparability and analytical evidence: Strength of similarity package and product characterization.
  • Clinical bridging: When required, it impacts timelines and cost.
  • Manufacturing scale and comparability stability: Process control and variation management are critical.
  • Patent landscape: Method-of-use and process patents can be relevant for biologics.

Commercial implication

  • For innovators, biosimilar threats are best managed by lifecycle strategies and indication expansion where claims are kept active. For biosimilar entrants, dossier defensibility and manufacturing readiness are essential.

Which Mexico regulatory opportunities exist for branded originators and which for generic manufacturers?

Branded originators: where opportunities concentrate

  • Lifecycle management: Formulation upgrades, dosing simplification, and indication expansions supported by enforceable IP.
  • Payer contracting: Secure formulary inclusion and procurement preference via demonstrated clinical value and pharmacoeconomic positioning.
  • Quality narrative: COFEPRIS approvals can be leveraged with high-confidence manufacturing and stability documentation to reduce post-approval enforcement risk.

Generic manufacturers: where opportunities concentrate

  • Portfolio expansion through fast approvals: Win by filing dossiers with minimal iteration.
  • Platform manufacturing: Use shared facility and validated CMC systems to shorten review cycles.
  • Substitution and channel strategy: Align pharmacist and wholesaler distribution practices to substitution mechanics.

What are the biggest regulatory challenges for generics in Mexico?

The main challenges are time-to-approval, product quality perception, and the legal-technical interface between IP and regulatory reliance.

Top operational and regulatory challenges

  • Dossier iteration risk: COFEPRIS can request clarifications on CMC, bioequivalence evidence, and labeling.
  • GMP compliance and traceability: APIs and intermediates must be traceable and controlled.
  • Bioequivalence variability: BA/BE design choices affect success rates.
  • Commercial execution under substitution rules: Even with approval, pharmacy substitution patterns and payer procurement policies can delay volume capture.
  • Labeling and safety language: Compliance defects can stall launches or require relabeling.

Which litigation and enforcement patterns affect drug market entry in Mexico?

Patent disputes and regulatory linkage interactions create a durable uncertainty layer. Litigation outcomes influence whether COFEPRIS can proceed with protected-status applications and whether generic launch dates slip.

Litigation patterns with entry consequences

  • Injunction-style relief or regulatory stays: Can delay approvals even when generic applicants file promptly.
  • Patent scope disputes: Claim construction and whether a generic product design falls outside the scope affects legal outcomes.
  • Secondary patent focus: Claim sets tied to specific formulations and use cases are frequently used to extend exclusivity.

How does Mexico’s reimbursement and procurement policy shift branded share toward generics?

Payer behavior in Mexico determines whether a generic can scale after approval. When public procurement or formulary rules prefer lower priced products, generics gain rapid share. When clinical guidelines or physician preferences restrict switching, brands retain volume longer.

Mechanisms that drive generic share

  • Lower net pricing in procurement: Generic price erosion is systematic once formulary inclusion is achieved.
  • Switching pressure: Economic incentives and substitution rules support switching.
  • Therapeutic interchange: Some classes allow substitution more readily than others based on clinical considerations.

Brand defense levers

  • Offer competitive pricing, rebates, or value-based contracting to maintain formulary positions.
  • Maintain evidence packages that support guideline adherence for key sub-indications.

What pricing controls and market access constraints shape net revenues in Mexico?

Mexico’s pricing environment can compress margins quickly after generics enter, increasing the importance of net pricing and volume management. For IP holders, effective net pricing depends on timing and contracting power. For generic entrants, success depends on launch pricing discipline and procurement readiness.

Key pricing and access effects

  • Net price erosion after generic entry: Margin compresses; revenue depends on volume capture and supply continuity.
  • Procurement-driven demand shocks: Launch timing affects allocation and contract renewal cycles.
  • Channel mix changes: Wholesaler and pharmacy adoption of substitutes drives sales velocity.

How many patents typically cover a branded small molecule in Mexico, and what does that mean for generic risk?

Patent estate size is product-dependent, but for many originator small molecules, the typical structure is compound plus several lifecycle patents. The strategic takeaway is that generics often face a multi-patent negotiation and enforcement backdrop, not a single expiry date.

Generic risk implications

  • Non-infringement carve-outs: If generics can design around secondary patents, entry can occur earlier even if the primary compound is still protected.
  • Delay due to multi-patent linkage: Even if one patent expires, remaining active patents can keep the product protected through COFEPRIS linkage.

How does Mexico’s IP and regulatory framework compare with the US and EU for drug entry?

US comparison (high level)

  • US entry is driven by Hatch-Waxman and Paragraph IV litigation mechanics.
  • Mexico uses a linkage approach through COFEPRIS and Mexican patent enforcement, where timing uncertainty can remain high and challenge pathways are structurally different.

EU comparison (high level)

  • EU authorization via EMA routes; national-level pricing and reimbursement drive adoption.
  • Mexico’s authorization and market access enforcement sit more directly under COFEPRIS processes that intersect with patent protection in practice.

Actionable strategic insight

  • Investors should treat Mexico as its own entry case with linkage-driven timing risk, not as a simple extrapolation from US Paragraph IV schedules.

Which therapeutic areas offer the strongest Mexico branded-generic opportunities?

  • Cardiometabolic: Large patient pools and procurement-driven price sensitivity support generic expansion. Brands defend with dosing regimens and line extensions.
  • Oncology and complex specialty: Biosimilars and biologic entry are slower but can reshape market structure with significant cost impacts.
  • Infectious disease: Inventory and procurement cycles favor fast approvals; however, IP and formulation differences can delay consistent generic penetration.
  • Respiratory and CNS: Switch inertia can protect brands longer; generics can expand once interchange rules and clinician acceptance align.

What formulations are most often protected and how do they impact generic development in Mexico?

Formulation and dosage form protection is a key lever in Mexico, where product equivalence must meet quality and performance expectations.

Common formulation patent targets

  • Extended-release matrices and coatings
  • Stabilized salts or polymorph-controlled compositions
  • Particle size and dissolution-profile control
  • Breathable or transdermal delivery-specific compositions
  • Excipients that manage stability and bioavailability

Generic development consequence

  • Bioequivalence can be harder when a formulation patent constrains design space. Even a “bioequivalent” generic may still face IP infringement arguments if the formulation is within patent scope.

What manufacturing and supply chain barriers exist for launch success in Mexico?

Typical barriers

  • API sourcing and stability: API quality and stability data must support ongoing shelf life.
  • GMP inspection readiness: Facilities must pass Mexican requirements.
  • Cold chain and distribution: For temperature-sensitive products, distribution compliance affects launch success.
  • Batch consistency: Post-approval changes can trigger regulatory burdens.

Commercial consequence

  • Supply delays can cause lost procurement cycles, which drives revenue risk more than approval timing alone.

Key Takeaways

  • Mexico’s branded share is resilient where clinical familiarity, procurement contracting, and formulation/method-of-use patents maintain switching friction; generic share grows fastest once regulatory linkage and patent barriers clear and substitution aligns with payer policy.
  • COFEPRIS dossier predictability and manufacturing readiness determine generic speed-to-market and post-approval stability.
  • Patent estates in Mexico typically include lifecycle formulation and use claims, creating multi-patent linkage risk rather than a single “expiry date” problem.
  • Biosimilars face higher technical and evidence hurdles than generics, increasing entry risk and extending commercialization uncertainty.
  • For licensing and investment, the most actionable framework is mapping IP claims to product attributes, stress-testing COFEPRIS dossier iteration risk, and modeling legal delay scenarios.

FAQs

1) What is the most common reason COFEPRIS delays generic approvals in Mexico?
CMC dossier gaps, bioequivalence evidence issues, and labeling compliance defects are the most frequent delay drivers.

2) Do patent expirations automatically allow generic launch in Mexico?
No. Ongoing secondary patents and regulatory linkage barriers can keep products protected in practice beyond first expiry.

3) How should companies think about reformulations in Mexico IP strategy?
Formulation upgrades often attract enforceable secondary patents, which can delay generic substitution even when the core active ingredient term is near expiry.

4) Are biosimilar launches faster than generic launches in Mexico?
Biosimilars generally take longer due to comparability evidence expectations, manufacturing complexity, and patent landscape breadth.

5) Does regulatory approval guarantee generic uptake in Mexico?
No. Payer procurement rules, substitution behavior, and net pricing determine whether approved products capture volume quickly.

References (APA)

  1. COFEPRIS. (n.d.). Regulación sanitaria de medicamentos y documentos técnicos (orientación y marcos regulatorios). Comisión Federal para la Protección contra Riesgos Sanitarios.
  2. WIPO. (n.d.). Patents and pharmaceutical intellectual property frameworks (Mexico context). World Intellectual Property Organization.
  3. European Medicines Agency. (n.d.). Guideline and biosimilar regulatory guidance (comparative evidence framework). European Medicines Agency.
  4. PAHO/OPS. (n.d.). Health systems and medicines regulatory and market access materials for the Americas (Mexico-relevant overview). Pan American Health Organization.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links